Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Two-Arm, Placebo-Controlled, Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of LJPC-401 in Healthy Adults

Trial Profile

A Phase 1, Randomized, Double-Blind, Two-Arm, Placebo-Controlled, Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of LJPC-401 in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Hepcidin (Primary)
  • Indications Haemochromatosis; Iron overload
  • Focus Adverse reactions
  • Sponsors La Jolla Pharmaceutical Australia
  • Most Recent Events

    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 23 Jan 2018 According to the australian New Zealand Clinical Trials Registry, One multiple dose cohort was enrolled during study conduct.
    • 23 Jan 2018 Status changed from not yet recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top